Voglibose 0.30 mg + Glimepiride 1.00 mg + Metformin Hydrochloride 500.00 mg

APRIGLIM MV 1MG | 0.3MG is a fixed-dose combination medication that contains Voglibose (0.30mg/Tablet), Metformin Hydrochloride (500.00mg/Tablet), and Glimepiride (1.00mg/Tablet). It is prescribed for the management of type 2 diabetes mellitus. Voglibose inhibits alpha-glucosidase enzymes, delaying carbohydrate digestion and reducing postprandial glucose levels. Metformin, a biguanide, reduces hepatic glucose production and improves insulin sensitivity. Glimepiride stimulates insulin release from pancreatic beta cells. Together, these ingredients help lower blood sugar levels and improve glycemic control. APRIGLIM MV 1MG | 0.3MG is typically prescribed as an adjunct to diet and exercise for better diabetes management.

Take APRIGLIM MV 1MG | 0.3MG orally with meals, as directed by your doctor. It is important to follow the prescribed dosage and frequency. Do not self-adjust the medication without consulting your doctor.

Allopathic

The contents and information provided here are solely intended to provide a general overview of the products and medicines and must be used for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. The information contained herein should not be used as a substitute for the advice of a qualified physician. For all queries or doubts related to your medical condition, we highly recommend that you consult your registered medical practitioner.